Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 711 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma June 24, 2022 10 Tips for National Cancer Prevention Month February 10, 2021 Man Offers Free Lawn Mowing Service To Elderly And Veterans August 28, 2021 NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... November 18, 2025 Load more HOT NEWS Ending smoking could more than halve England’s cancer inequality gap Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... Patient Guide on Immunotherapy Side Effects and Their Management Now Available... A Message from the ESMO President
